FDA Accepts Type C Meeting for Doxorubicin-MNA in Basal Cell Carcinoma of the Skin
Written by
Cancer Network
Published
0
comments
0
min
D-MNA achieved complete clinical clearance in 60% of patients, with no dose-limiting toxicities or serious adverse effects observed in those with basal cell carcinoma of the skin.